HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Giulio Rizzoli Salvatore Mirone Paolo Ius Elvio Polesel Tomaso Bottio Loris Salvador Claudio Zussa Gino Gerosa Carlo Valfrè Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rizzoli, G. Articles by Valfrè, C. Search for Related Content PubMed PubMed Citation Articles by Rizzoli, G. Articles by Valfrè, C. Related Collections Valve disease

J Thorac Cardiovasc Surg 2006;132:602-609
© 2006 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease

Fifteen-year results with the Hancock II valve: A multicenter experience

^a Cardiac Surgery Unit, Ca Foncello Hospital of Treviso, Treviso, Italy
^b Cardiac Surgery Unit, University of Padova, Padova, Italy
^c Cardiac Surgery Unit, Umberto I° Hospital of Venice, Venice, Italy.

Received for publication March 8, 2006; revisions received April 30, 2006; accepted for publication May 17, 2006.

^_* Address for reprints: Giulio Rizzoli, MD, Via Giustiniani 2, Padova, Italy 35121. (Email: giulio.rizzoli{at}unipd.it).

OBJECTIVES: The purpose of this multi-institutional study was to review the 15-year outcome of patients who received isolated aortic or mitral valve replacement with the Hancock II bioprosthesis.

METHODS: From 1983 through 2002, 1274 patients underwent 1293 isolated valve replacements, 809 aortic valve replacements and 484 mitral valve replacements, at hospitals in the Venetian area (Padova, Treviso, and Venice). Mean age was 68 ± 8 years in patients undergoing aortic valve replacement and 66 ± 9 years in patients undergoing mitral valve replacement; 52% of patients undergoing aortic valve replacement and 63% of patients undergoing mitral valve replacement were in New York Heart Association class III or greater. Coronary artery disease was present in 32% of patients who had undergone aortic valve replacement and 18% of patients who had undergone mitral valve replacement. Follow-up included 8520 patient-years, with a median of 12 years, and was 97% complete.

RESULTS: Overall 15-year survival was 39.7% ± 2.4%, similar in both the aortic and mitral positions. Multivariable analysis of late survival showed the incremental risk of male sex, higher New York Heart Association class, coronary artery disease, and mitral position. Freedom from embolism was higher in the aortic position (81% ± 2.9% in aortic vs 72% ± 4.7% in mitral valve replacements). Freedom from endocarditis was similar in the aortic and mitral position (95% ± 1.2% vs 94% ± 1.7%). Freedom from reoperation (82% ± 3.7% vs 71% ± 5.0%) and from valve-related morbidity-mortality (52% ± 3.6% vs 36% ± 4.4%) was higher in patients who had undergone AVR. Actual freedom from structural valve deterioration for patients 60 years and older who had undergone aortic valve replacement was 96.5% ± 1.3% versus 88% ± 3.2% for patients who had undergone mitral valve replacement and 70% ± 7.5% versus 77.5% ± 5.3%, respectively, in younger patients. Multivariable Weibull analysis showed structural valve deterioration related to younger age and preoperative valve incompetence and inversely related to coronary artery disease.

CONCLUSION: Optimal 15-year durability can be expected in male patients 60 years and older who have undergone aortic valve replacement and in male patients 65 years and older who have undergone mitral valve replacement, extending safely the age limits for the use of this valve.

This article has been cited by other articles:

				W. R. E. Jamieson, V. M. Gudas, L. H. Burr, M. T. Janusz, G. J. Fradet, H. Ling, E. Germann, and S. V. Lichtenstein Mitral valve disease: if the mitral valve is not reparable/failed repair, is bioprosthesis suitable for replacement? Eur. J. Cardiothorac. Surg., January 1, 2009; 35(1): 104 - 110. [Abstract] [Full Text] [PDF]

				E. Pettenazzo, M. Valente, and G. Thiene Octanediol treatment of glutaraldehyde fixed bovine pericardium: evidence of anticalcification efficacy in the subcutaneous rat model Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 418 - 422. [Abstract] [Full Text] [PDF]

				M. L. Brown, H. V. Schaff, B. D. Lahr, C. J. Mullany, T. M. Sundt, J. A. Dearani, C. G. McGregor, and T. A. Orszulak Aortic valve replacement in patients aged 50 to 70 years: Improved outcome with mechanical versus biologic prostheses. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 878 - 884. [Abstract] [Full Text] [PDF]

				T. Bottio, M. Valente, G. Rizzoli, V. Tarzia, G. Bisleri, E. Pettenazzo, G. Gerosa, and G. Thiene Commissural dehiscence: a rare and peculiar cause of porcine valve structural deterioration. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1017 - 1022. [Abstract] [Full Text] [PDF]

				C. Valfre, G. Rizzoli, C. Zussa, P. Ius, E. Polesel, S. Mirone, T. Bottio, and G. Gerosa Clinical results of Hancock II versus Hancock Standard at long-term follow-up. J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 595 - 601.e2. [Abstract] [Full Text] [PDF]